Deep sequencing reveals microRNAs predictive of antiangiogenic drug response
Jesús García-Donás(Universidad San Pablo CEU), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), José Ángel Arranz(Hospital General Universitario Gregorio Marañón), Oliver Bechter(Universitair Ziekenhuis Leuven), María Apellániz-Ruiz(Navarrabiomed), Patrick Schöffski(KU Leuven), Daniel Castellano(Universidad Complutense de Madrid), Aranzazu González del Alba(Hospital Universitario Son Espases), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Emilio Esteban(Hospital Universitario Central de Asturias), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Osvaldo Graña‐Castro(Spanish National Cancer Research Centre), Lucía Inglada‐Pérez(Spanish National Cancer Research Centre), David G. Pisano(Spanish National Cancer Research Centre), Miguel Ángel Climent(Radboud University Nijmegen), Luis J. Leandro‐García(Spanish National Cancer Research Centre), Susana Hernando(Hospital Universitario Fundación Alcorcón), Manuel M. Morente(Spanish National Cancer Research Centre)
Cited by 48
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k